Global Celiac Drugs Market by Type (First Line Of Treatment, Second Line Of Treatment), By Application (Men, Women, Children) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
The Global Celiac Drugs Market size is projected to grow at a CAGR of 5.8% during the forecast period 2018-2028. The growth in this market can be attributed to the increasing prevalence of celiac disease, raising awareness about celiac disease, and technological advancements in the field of celiac drugs. In this report, we have segmented the global celiac drugs market on the basis of type, application, and region.
Celiac drugs are medications that are used to treat celiac disease. Celiac disease is a condition in which the body cannot tolerate gluten, a protein found in wheat, barley, and rye. When people with celiac disease eat foods that contain gluten, they may experience abdominal pain, diarrhea, bloating, and fatigue. Celiac disease is a condition that causes damage to the lining of the small intestine and prevents it from absorbing parts of food that are important for staying healthy. People who have celiac disease cannot tolerate a protein called gluten, which is found in wheat, rye, and barley. When people with celiac disease eat foods or use products that contain gluten, their immune system responds by damaging the small intestine.
On the basis of Type, the global celiac drugs market is segmented into first line of treatment and second line of treatment.
First Line Of Treatment:
First line of treatment is the initial course of therapy that is recommended for a particular disease or condition. It is usually the most effective and least invasive form of treatment. First-line treatments are typically used before second-line treatments are considered. The first line of treatment for celiac disease is a gluten-free diet. This means avoiding all foods that contain wheat, rye, and barley. People with celiac disease must be careful to avoid even trace amounts of gluten in their diet. The gluten-free diet is the only currently available treatment for celiac disease. It is a lifelong diet that requires careful planning and labels reading to avoid hidden sources of gluten.
Second Line Of Treatment:
Second line of treatment is a type of celiac drug that is used when the first line of treatment fails. Second-line treatments are typically more aggressive and have more side effects than first-line treatments. Some common second-line treatments for celiac disease include immunosuppressants, anti-inflammatory drugs, and biological therapies. Second line of treatment for celiac disease is generally a gluten-free diet. This means eliminating all foods that contain gluten from the diet. This can be a challenge, as gluten is found in many common foods, such as bread, pasta, cereal, and baked goods.
On the basis of Application, the global celiac drugs market is segmented into men, women, and children.
On the basis of Region, the global celiac drugs market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The celiac drugs market in North America is expected to grow at a significant rate during the forecast period. This growth can be attributed to the rising prevalence of celiac disease and the availability of advanced treatments in this region. Moreover, increasing awareness about the disease and its treatment options is also fueling the market growth in North America. The European region is expected to be the second-largest market for celiac drugs due to the high prevalence of celiac disease in this region. The prevalence of the celiac disease is estimated to be about one in every 100 people in Europe. Moreover, the availability of new and innovative treatments and the increasing awareness about celiac disease are also expected to drive market growth in this region.
The Asia Pacific region is expected to be the fastest-growing market for celiac drugs due to the increasing prevalence of celiac disease in this region. The high growth of this region is attributed to the growing awareness about celiac disease and the rise in disposable incomes. China and India are expected to be the major contributors to the market growth in this region. The Middle East & Africa region is expected to witness moderate growth during the forecast period due to the low prevalence of celiac disease in this region. However, the availability of new and innovative treatments and the increasing awareness about celiac disease are expected to drive market growth in this region.
Growth Factors For The Global Celiac Drugs Market:
The global celiac drugs market is growing due to the increase in the number of people suffering from celiac disease. The number of people diagnosed with celiac disease has been increasing over the years, owing to the awareness about the condition and the availability of better diagnostic tools. This has resulted in an increased demand for celiac drugs globally. Moreover, the development of new and improved treatments for celiac disease is another factor that is expected to drive the growth of the global celiac drugs market during the forecast period.
Up Market Research published a new report titled “Celiac Drugs Market research report which is segmented by Types (First Line Of Treatment, Second Line Of Treatment), By Applications (Men, Women, Children), By Players/Companies ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer, Biogen, BioLineRx, Biotest, Bristol-Myers Squibb, Celgene, Celimmune, F Hoffmann-La Roche, ImmunogenX, Immunomedics, ImmusanT, Innovate Biopharmaceuticals, Johnson & Johnson, Kedrion Biopharma, LFB Group, Merck, Novartis”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Celiac Drugs Market Research Report |
| By Type | First Line Of Treatment, Second Line Of Treatment |
| By Application | Men, Women, Children |
| By Companies | ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer, Biogen, BioLineRx, Biotest, Bristol-Myers Squibb, Celgene, Celimmune, F Hoffmann-La Roche, ImmunogenX, Immunomedics, ImmusanT, Innovate Biopharmaceuticals, Johnson & Johnson, Kedrion Biopharma, LFB Group, Merck, Novartis |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 228 |
| Number of Tables & Figures | 160 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Celiac Drugs Market Report Segments:
The market is segmented by Type First Line Of Treatment, Second Line Of Treatment and By Application Men, Women, Children.
Some of the companies that are profiled in this report are:
- ADMA Biologics
- Amgen
- Anthera Pharmaceuticals
- Bayer
- Biogen
- BioLineRx
- Biotest
- Bristol-Myers Squibb
- Celgene
- Celimmune
- F Hoffmann-La Roche
- ImmunogenX
- Immunomedics
- ImmusanT
- Innovate Biopharmaceuticals
- Johnson & Johnson
- Kedrion Biopharma
- LFB Group
- Merck
- Novartis
Celiac Drugs Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Celiac Drugs Market
Overview of the regional outlook of the Celiac Drugs Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Celiac Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Celiac Drugs Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
- By Type:
1. First Line Of Treatment
2. Second Line Of Treatment
7. By Application:1. Men
2. Women
3. Children
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Celiac Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Celiac Drugs Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Celiac Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Celiac Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Celiac Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Celiac Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Celiac Drugs Market Size & Forecast, 2018-2028
4.5.1 Celiac Drugs Market Size and Y-o-Y Growth
4.5.2 Celiac Drugs Market Absolute $ Opportunity
Chapter 5 Global Celiac Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Celiac Drugs Market Size Forecast by Type
5.2.1 First Line Of Treatment
5.2.2 Second Line Of Treatment
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Celiac Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Celiac Drugs Market Size Forecast by Applications
6.2.1 Men
6.2.2 Women
6.2.3 Children
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Celiac Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Celiac Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Celiac Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Celiac Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Celiac Drugs Market Size Forecast by Type
9.6.1 First Line Of Treatment
9.6.2 Second Line Of Treatment
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Celiac Drugs Market Size Forecast by Applications
9.10.1 Men
9.10.2 Women
9.10.3 Children
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Celiac Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Celiac Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Celiac Drugs Market Size Forecast by Type
10.6.1 First Line Of Treatment
10.6.2 Second Line Of Treatment
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Celiac Drugs Market Size Forecast by Applications
10.10.1 Men
10.10.2 Women
10.10.3 Children
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Celiac Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Celiac Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Celiac Drugs Market Size Forecast by Type
11.6.1 First Line Of Treatment
11.6.2 Second Line Of Treatment
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Celiac Drugs Market Size Forecast by Applications
11.10.1 Men
11.10.2 Women
11.10.3 Children
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Celiac Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Celiac Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Celiac Drugs Market Size Forecast by Type
12.6.1 First Line Of Treatment
12.6.2 Second Line Of Treatment
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Celiac Drugs Market Size Forecast by Applications
12.10.1 Men
12.10.2 Women
12.10.3 Children
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Celiac Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Celiac Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Celiac Drugs Market Size Forecast by Type
13.6.1 First Line Of Treatment
13.6.2 Second Line Of Treatment
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Celiac Drugs Market Size Forecast by Applications
13.10.1 Men
13.10.2 Women
13.10.3 Children
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Celiac Drugs Market: Competitive Dashboard
14.2 Global Celiac Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 ADMA Biologics
14.3.2 Amgen
14.3.3 Anthera Pharmaceuticals
14.3.4 Bayer
14.3.5 Biogen
14.3.6 BioLineRx
14.3.7 Biotest
14.3.8 Bristol-Myers Squibb
14.3.9 Celgene
14.3.10 Celimmune
14.3.11 F Hoffmann-La Roche
14.3.12 ImmunogenX
14.3.13 Immunomedics
14.3.14 ImmusanT
14.3.15 Innovate Biopharmaceuticals
14.3.16 Johnson & Johnson
14.3.17 Kedrion Biopharma
14.3.18 LFB Group
14.3.19 Merck
14.3.20 Novartis
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Celiac Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Celiac Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Celiac Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Celiac Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Celiac Drugs Market Size & Forecast, 2018-2028
4.5.1 Celiac Drugs Market Size and Y-o-Y Growth
4.5.2 Celiac Drugs Market Absolute $ Opportunity
Chapter 5 Global Celiac Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Celiac Drugs Market Size Forecast by Type
5.2.1 First Line Of Treatment
5.2.2 Second Line Of Treatment
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Celiac Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Celiac Drugs Market Size Forecast by Applications
6.2.1 Men
6.2.2 Women
6.2.3 Children
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Celiac Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Celiac Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Celiac Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Celiac Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Celiac Drugs Market Size Forecast by Type
9.6.1 First Line Of Treatment
9.6.2 Second Line Of Treatment
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Celiac Drugs Market Size Forecast by Applications
9.10.1 Men
9.10.2 Women
9.10.3 Children
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Celiac Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Celiac Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Celiac Drugs Market Size Forecast by Type
10.6.1 First Line Of Treatment
10.6.2 Second Line Of Treatment
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Celiac Drugs Market Size Forecast by Applications
10.10.1 Men
10.10.2 Women
10.10.3 Children
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Celiac Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Celiac Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Celiac Drugs Market Size Forecast by Type
11.6.1 First Line Of Treatment
11.6.2 Second Line Of Treatment
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Celiac Drugs Market Size Forecast by Applications
11.10.1 Men
11.10.2 Women
11.10.3 Children
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Celiac Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Celiac Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Celiac Drugs Market Size Forecast by Type
12.6.1 First Line Of Treatment
12.6.2 Second Line Of Treatment
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Celiac Drugs Market Size Forecast by Applications
12.10.1 Men
12.10.2 Women
12.10.3 Children
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Celiac Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Celiac Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Celiac Drugs Market Size Forecast by Type
13.6.1 First Line Of Treatment
13.6.2 Second Line Of Treatment
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Celiac Drugs Market Size Forecast by Applications
13.10.1 Men
13.10.2 Women
13.10.3 Children
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Celiac Drugs Market: Competitive Dashboard
14.2 Global Celiac Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 ADMA Biologics
14.3.2 Amgen
14.3.3 Anthera Pharmaceuticals
14.3.4 Bayer
14.3.5 Biogen
14.3.6 BioLineRx
14.3.7 Biotest
14.3.8 Bristol-Myers Squibb
14.3.9 Celgene
14.3.10 Celimmune
14.3.11 F Hoffmann-La Roche
14.3.12 ImmunogenX
14.3.13 Immunomedics
14.3.14 ImmusanT
14.3.15 Innovate Biopharmaceuticals
14.3.16 Johnson & Johnson
14.3.17 Kedrion Biopharma
14.3.18 LFB Group
14.3.19 Merck
14.3.20 Novartis
Segments Covered in the Report
The global Celiac Drugs market has been segmented based on
By Types
The global Celiac Drugs market has been segmented based on
By Types
- First Line Of Treatment
- Second Line Of Treatment
- Men
- Women
- Children
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- ADMA Biologics
- Amgen
- Anthera Pharmaceuticals
- Bayer
- Biogen
- BioLineRx
- Biotest
- Bristol-Myers Squibb
- Celgene
- Celimmune
- F Hoffmann-La Roche
- ImmunogenX
- Immunomedics
- ImmusanT
- Innovate Biopharmaceuticals
- Johnson & Johnson
- Kedrion Biopharma
- LFB Group
- Merck
- Novartis
Our Clients
Related Reports
Some other reports from this category!
